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Background-—Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of antihyperglycemic agents that improve
glycemic control by increasing glycosuria. Additional benefits beyond glucose lowering include significant improvements in seated
clinic blood pressure (BP), partly attributed to their diuretic-like actions. Less known are the effects of this class on 24-hour
ambulatory BP, which is a better predictor of cardiovascular risk than seated clinic BP.
Methods and Results-—We performed a meta-analysis of randomized, double-blind, placebo-controlled trials to investigate the
effects of SGLT2 inhibitors on 24-hour ambulatory BP. We searched all studies published before August 17, 2016, which reported
24-hour ambulatory BP data. Mean differences in 24-hour BP, daytime BP, and nighttime BP were calculated by a random-effects
model. SGLT2 inhibitors significantly reduce 24-hour ambulatory systolic and diastolic BP by 3.76 mm Hg (95% CI, 4.23 to
2.34; I2=0.99) and 1.83 mm Hg (95% CI, 2.35 to 1.31; I2=0.76), respectively. Significant reductions in daytime and
nighttime systolic and diastolic BP were also found. No association between baseline BP or change in body weight were observed.
Conclusions-—This meta-analysis shows that the reduction in 24-hour ambulatory BP observed with SGLT2 inhibitors is a class
effect. The diurnal effect of SGLT2 inhibitors on 24-hour ambulatory BP may contribute to their favorable effects on cardiovascular
outcomes. ( J Am Heart Assoc. 2017;6:e005686. DOI: 10.1161/JAHA.117.005686.)
Key Words: ambulatory blood pressure monitoring • diabetes mellitus • diabetic therapy/glitazones • high blood pressure •
hypertension • metformin • sodium-glucose cotransporter 2 inhibitors
S odium-glucose cotransporter 2 (SGLT2) mediates glu-cose uptake in the early proximal tubule of the kidney
and is responsible for the majority (80–90%) of glucose
reabsorption at the glomerulus level.1 The remaining 10% to
20% is then reabsorbed by SGLT1. In patients with diabetes
mellitus, inhibitors of SGLT2 improve hyperglycemia by
increasing glycosuria. Currently, 3 SGLT2 inhibitors have
been approved by the US Food and Drug Administration for
the treatment of type 2 diabetes mellitus as adjuncts to diet
and exercise to improve glycemic control: canagliflozin,
dapagliflozin, and empagliflozin. Notably, empagliflozin has
the highest selectivity for SGLT2 compared with canagliflozin
and dapagliflozin.2
In the Empagliflozin, Cardiovascular Outcomes, and Mor-
tality in Type 2 Diabetes (EMPA-REG OUTCOME) trial,3
empagliflozin reduced total and cardiovascular mortality in
patients with type 2 diabetes mellitus compared with placebo,
an effect that was mainly driven by the beneficial effects on
heart failure. These impressive data have recently resulted in
a label change for empagliflozin to highlight the reduction in
cardiovascular mortality risk.4 However, the cardiovascular
benefits of empagliflozin cannot be justified by the improve-
ment in glycemic control alone, which suggests the presence
of non-glucose-lowering effects of empagliflozin.
One of the most consistently reported non-glucose-
lowering effects of SGLT2 inhibitors is the reduction of
systemic arterial blood pressure (BP). A recent meta-analysis
of 27 randomized controlled trials (RCTs) concluded that, in
patients with type 2 diabetes mellitus, SGLT2 inhibitors
improve systolic BP by 4 mm Hg (95% CI, 4.4 to 3.5)
and diastolic BP by 1.6 mm Hg (95% CI, 1.9 to 1.3).5
The exact BP reduction-related mechanisms of SGLT2
inhibitors have not been fully elucidated. However, it
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has been suggested that inhibition of glucose-sodium reab-
sorption in the proximal tubule results in an osmotic diuresis
and decreased BP.6
Additional studies have also observed that SGLT2 inhibi-
tors improve 24-hour ambulatory BP. Importantly, 24-hour
ambulatory BP is a better predictor of cardiovascular risk and
mortality than seated clinic BP and therefore, possibly, a
more-appropriate therapeutic target.7 Moreover, 24-hour
ambulatory BP can identify subjects with masked hyperten-
sion, which is associated with increased cardiovascular risk
and is more prevalent in patients with diabetes mellitus.8,9
Data on the effects of SGLT2 inhibition on 24-hour ambulatory
BP are confined to relatively small studies. The purpose of this
meta-analysis was to determine the magnitude of the effect
SGLT2 inhibitors exert on 24-hour ambulatory BP.
Methods
This meta-analysis conforms to standard guidelines and was
written in accord with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses statement.10
Figure 1. PRISMA diagram of study selection process. ABPM indicates ambulatory blood pressure
monitoring; DM, type 2 diabetes mellitus; RCT, randomized, controlled trial; Tx, treatment.
Clinical Perspective
What is New?
• This meta-analysis demonstrates that Sodium-glucose
cotransporter 2 inhibitors, as a class, significantly reduce
24-hour ambulatory blood pressure, which further supports
their favorable cardiovascular profile.
What are the Clinical Implications?
• The decrease in 24-hour ambulatory blood pressure
observed with Sodium-glucose cotransporter 2 inhibitors
further emphasizes the need for close monitoring of blood
pressure and volume status, especially in patients receiving
concomitant diuretic therapy.
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Literature Search
A systematic search of 3 databases was conducted along
with a search of the reference lists of the retrieved
publications, in order to identify published articles address-
ing the topic. Databases searched included PubMed/Med-
line, Web of Science, and The Cochrane Database of Clinical
Trials. The articles included were limited to the English
language and those published anytime from the inception of
each database to present. The search was broken into 3
concept groups. One group encompassed the terminology
used to describe “sodium-glucose cotransporter 2 inhibi-
tors,” another covered the terms relevant to “blood
pressure,” and a third addressed “randomized controlled
trials.” Medical Subject Headings (MeSH) and equivalent
controlled vocabulary and keywords were utilized in each
database. The last search of the databases was conducted
on August 17, 2016.
Study Selection
Three authors (D.L.D., W.L.B., and L.F.B.) reviewed all
potentially relevant articles in a parallel manner by using a
priori defined criteria. Studies were eligible for inclusion in the
meta-analysis if they met the following criteria: (1) RCT in
humans; (2) evaluated a SGLT2 inhibitor compared with either
placebo or an active control; and (3) reported data on changes
in 24-hour ambulatory BP from baseline in a form suitable for
pooling. Only data from peer-reviewed publications were
considered for inclusion in this analysis.
Data Abstraction and Validity Assessment
For each included study, 2 authors (D.L.D., L.F.B.) used a
standardized abstraction tool to extract data for the analysis,
with disagreements resolved by a third investigator (M.K.).
Information collected from each study included author, year of
publication, study design, duration of follow-up, population
and setting, sample size, SGLT2 inhibitor evaluated, and
concomitant antihyperglycemic therapies. Data on changes in
24-hour BP were obtained. Missing data were collected
through a search of the study results reported on clinicaltri-
als.gov. Two reviewers (D.L.D., L.F.B.) assessed the quality of
each study by answering “yes,” “no,” or “unclear” to 11
questions regarding similarity of baseline populations, ran-
domization, allocation concealment, blinding of study partic-
ipants and personnel, outcome adjudication, completeness of
follow-up, and conflicts of interest using the Methods Guide
for Comparative Effectiveness Reviews.11 Studies were given
an overall score of good, fair, or poor with disagreements
resolved through discussion.
Table 1. Baseline Characteristics of Trials Evaluating SGLT2 Inhibitors and 24-Hour Ambulatory Blood Pressure
Study Name Study Design SGLT2 Group n
Duration
(Weeks)
Average
Age (Y)
Baseline
24-Hour SBP
Baseline
24-Hour DBP
Baseline
Daytime SBP
Baseline
Nighttime SBP
Lambers-Heerspink
et al (2013)16
R, DB, PC DAPA 10 mg/d 24 12 52.79.4 13112 777 13812 12013
Placebo 25 58.09.5 12712 747 13112 11715
Amin
et al (2015)20
R, DB, PC ERTU 1 mg/d 39 4 54.47.0 133.11.7 78.61.3 NR NR
ERTU 5 mg/d 38 53.89.9 135.01.9 80.11.4
ERTU 25 mg/d 39 52.56.6 135.51.9 80.31.3
Placebo 38 55.16.7 136.12.5 81.81.5
Tikkanen
et al (2015)19
R, DB, PC EMPA 10 mg/d 276 12 60.68.5 131.313.0 75.18.3 NR NR
EMPA 25 mg/d 276 59.99.7 131.212.1 74.67.5
Placebo 271 60.38.8 131.711.8 75.27.5
Townsend
et al (2016)15
R, DB, PC CANA 100 mg/d 57 6 57.88.7 136.511.5 78.08.1 NR NR
CANA 300 mg/d 56 58.36.9 139.610.6 79.37.9
Placebo 56 59.69.5 136.710.3 78.47.3
Weber
et al (2016)18
R, DB, PC DAPA 10 mg/d 187 12 56.0 (51–62) 146.510.4 NR NR NR
Placebo 186 57.0 (50–62) 149.212.7
Weber
et al (2016)17
R, DB, PC DAPA 10 mg/d 267 12 55.68.4 145.911.7 87.06.9 149.111.6 139.714.7
Placebo 263 56.28.9 146.611.7 87.26.7 150.41.2 139.115.1
CANA indicates canagliflozin; DAPA, dapagliflozin; DB, double-blind; DBP, diastolic blood pressure; EMPA, empagliflozin; ERTU, ertugliflozin; NR, not reported; PC, placebo-controlled; R,
randomized; SBP, systolic blood pressure; SGLT2, sodium-glucose cotransporter 2 inhibitor.
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Statistical Analysis
Meta-analyses were performed on the mean changes from
baseline in 24-hour systolic and diastolic BP, daytime
systolic and diastolic BP, and nighttime systolic and
diastolic BP. All continuous data are reported as a mean
difference and accompanying 95% CI and was pooled using
a Hartung-Knapp method12 random-effects model using the
“meta” package in R (version 3.1.3; The R Project for
Statistical Computing). We reported doses for each drug,
regardless of its regulatory status. We assessed presence
of statistical heterogeneity using the Cochrane P value
(P<0.10 significant) and the degree of heterogeneity
using the I2 statistic with a value >50% considered
substantial.13 Contour plots were constructed as a visual
representation of bias in the main results (24-hour systolic
and diastolic BP), and we used Egger’s test of asymmetry
of the plots.14
Subgroup analyses were performed by pooling data for
each individual SGLT-2 inhibitor separately and assessing the
pooled between-group variance. We also conducted random-
effects metaregression to evaluate whether the BP effects
observed with the SGLT-2 inhibitors were associated with
either baseline 24-hour ambulatory BP or changes in body
weight during the trial. Additional variables, such as percent
patients with hypertension at baseline and urinary sodium
excretion, were not sufficiently reported to allow for metare-
gression to be performed.
Results
Study Selection and Characteristics
The literature search process and results are shown in
Figure 1. A total of 6 randomized, double-blind, placebo-
controlled studies were included in the analysis (Table 1).15–20
Of these, 3 RCTs (n=952) evaluated dapagliflozin,16–18 1 RCT
(n=823) evaluated empagliflozin,19 1 RCT (n=169) evaluated
canagliflozin,15 and 1 RCT (n=154) evaluated ertugliflozin.20
The dose of dapagliflozin used in each study was 10 mg/day,
and sample sizes ranged from 49 to 530 participants.16–18
Doses of empagliflozin, canagliflozin, and ertugliflozin ranged
from 10 to 25, 100 to 300, and 1 to 25, respectively.15,19,20 Key
clinical data for each of the included studies are provided in
detail in Table 2.15–20 The quality of each study was deter-
mined to be “good” with no disagreements between the
reviewers.
Table 2. Reported Clinical End Point Data
Study Name SGLT2 Group n
Change in
24-Hour
SBP From
Baseline
Change in
24-Hour
DBP From
Baseline
Change in
Daytime
SBP From
Baseline
Change in
Daytime
DBP From
Baseline
Change in
Nighttime
SBP From
Baseline
Change in
Nighttime
DBP From
Baseline
Lambers-
Heerspink
et al (2013)16
DAPA 10 mg/d 24 5.611.62 NR 8.812.25 NR 1.912.5 NR
Placebo 25 0.79.18 0.89.31 0.611.48
Amin
et al (2015)20
ERTU 1 mg/d 39 2.974.62 1.93.03 2.94.78 2.13.19 2.65.89 1.64.3
ERTU 5 mg/d 38 44.87 2.33.15 3.65.35 1.93.46 3.66.45 2.64.72
ERTU 25 mg/d 39 3.694.62 1.53.03 4.24.64 1.73.19 2.46.05 0.94.46
Placebo 38 0.14.4 0.83.30 0.85.19 0.93.3 0.46.29 0.94.40
Tikkanen
et al (2015)19
EMPA 10 mg/d 276 2.998.86 1.14.96 3.49.55 1.285.41 2.2210.21 0.86.21
EMPA 25 mg/d 276 3.599.30 1.324.96 4.129.55 1.585.35 2.4711.09 0.756.32
Placebo 271 0.428.25 0.35.06 0.388.74 0.265.36 0.5110.22 0.366.8
Townsend
et al (2016)15
CANA 100 mg/d 57 4.788.33 2.184.87 5.058.66 2.395.41 4.3311.51 1.736.48
CANA 300 mg/d 56 7.3111.41 3.276.46 7.3611.66 3.236.56 6.9812.88 3.428.06
Placebo 56 1.269.86 0.265.35 0.659.87 0.25.26 3.4912.47 0.987.75
Weber
et al (2016)18
DAPA 10 mg/d 187 11.3321.9 7.5613.95 NR NR NR NR
Placebo 186 6.8821.5 5.5713.64
Weber
et al (2016)17
DAPA 10 mg/d 267 9.6220.1 6.1513.73 1020.43 NR 8.822.88 NR
Placebo 263 6.7320.1 5.5313.78 6.920.69 6.523.17
CANA indicates canagliflozin; DAPA, dapagliflozin; DBP, diastolic blood pressure; EMPA, empagliflozin; ERTU, ertugliflozin; NR, not reported; SBP, systolic blood pressure; SGLT2, sodium-
glucose cotransporter 2 inhibitor.
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Quantitative Data Synthesis
24-hour BP
When the 6 RCTs were pooled, SGLT2 inhibitor use was
associated with a statistically significant 3.76 mm Hg
reduction in 24-hour systolic BP when compared with placebo
(95% CI, 4.23 to 2.34; I2=0.99; Figure 2).15–20 The mean
differences observed with canagliflozin, dapagliflozin, empa-
gliflozin, and ertugliflozin were 4.65 mm Hg (95% CI,
20.63 to 11.33), 3.73 mm Hg (95% CI, 6.38 to
Study
Random effects model
Heterogeneity: I-squared=0%, p=0.9927
drug = CANA
drug = DAPA
drug = EMPA
drug = ERTU
Random effects model
Random effects model
Random effects model
Random effects model
Heterogeneity: I-squared=0%, p=0.4346
Heterogeneity: I-squared=0%, p=0.7842
Heterogeneity: I-squared=0%, p=0.6355
Heterogeneity: I-squared=0%, p=0.8756
Townsend, et al., 201615 (100mg)
Townsend, et al., 201615 (300mg)
Heerspink, et al., 201316 (10mg)
Weber, et al., 201618 (10mg)
Weber, et al., 201617 (10mg)
Tikkanen, et al., 201519 (10mg)
Tikkanen, et al., 201519 (25mg)
Amin, et al., 201520 (1mg)
Amin, et al., 201520 (5mg)
Amin, et al., 201520 (25mg)
Total
1259
113
478
552
116
57
56
24
187
267
276
276
39
38
39
Mean
-4.78
-7.31
-5.60
-11.33
-9.62
-2.99
-3.59
-2.97
-4.00
-3.69
SD
8.33
11.41
11.62
21.90
20.10
8.86
9.30
4.62
4.87
4.62
SGLT-2
Total
839
56
474
271
38
28
28
25
186
263
135.50
135.50
12.67
12.67
12.67
Mean
-1.26
-1.26
-0.70
-6.88
-6.73
0.42
0.42
0.10
0.10
0.10
SD
9.86
9.86
9.18
21.50
20.10
8.25
8.25
4.40
4.40
4.40
Placebo
-10 -5 0 5 10
Mean difference
24-hr SBP
MD
-3.76
-4.65
-3.73
-3.70
-3.65
-3.52
-6.05
-4.90
-4.45
-2.89
-3.41
-4.01
-3.07
-4.10
-3.79
95%-CI
[ -4.23; -3.30]
[-20.63; 11.33]
[ -6.38; -1.07]
[ -7.52;  0.11]
[ -4.96; -2.34]
[ -7.76;  0.72]
[-10.77; -1.33]
[-10.78;  0.98]
[ -8.85; -0.05]
[ -6.31;  0.53]
[ -5.15; -1.67]
[ -5.78; -2.24]
[ -5.89; -0.25]
[ -6.98; -1.22]
[ -6.61; -0.97]
Figure 2. Effect of SGLT2 inhibitors on 24-hour systolic blood pressure. CANA indicates canagliflozin; DAPA, dapagliflozin; EMPA,
empagliflozin; ERTU, ertugliflozin; MD, mean difference; SBP, systolic blood pressure; SGLT2, sodium-glucose cotransporter 2 inhibitor.
Figure 3. Contour-enhanced funnel plots of 24-hour systolic blood pressure.
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1.07), 3.70 mm Hg (95% CI, 7.52 to 0.11), and
3.65 mm Hg (95% CI, 4.96 to 2.34), respectively. No
significant difference between individual SGLT-2 inhibitors
was noted (P=0.90). There was also no strong evidence of
small-study effects (Egger’s test, P=0.25; Figure 3).
Only 4 of the 6 RCTs reported data for 24-hour diastolic
BP. SGLT2 inhibitor use was associated with a statistically
significant 1.83 mm Hg reduction in 24-hour diastolic BP
when compared with placebo (95% CI, 2.35 to 1.31;
I2=0.76; Figure 4).15,17–20 The mean differences observed
Study
Random effects model
Heterogeneity: I-squared=0%, p=0.759
drug = CANA
drug = DAPA
drug = EMPA
drug = ERTU
Random effects model
Random effects model
Random effects model
Random effects model
Heterogeneity: I-squared=0%, p=0.5427
Heterogeneity: I-squared=0%, p=0.462
Heterogeneity: I-squared=0%, p=0.768
Heterogeneity: I-squared=0%, p=0.8655
Townsend, et al., 201615 (100mg)
Townsend, et al., 201615 (300mg)
Weber, et al., 201618 (10mg)
Weber, et al., 201617 (10mg)
Tikkanen, et al., 201519 (10mg)
Tikkanen, et al., 201519 (25mg)
Amin, et al., 201520 (1mg)
Amin, et al., 201520 (5mg)
Amin, et al., 201520 (25mg)
Total
1235
113
454
552
116
57
56
187
267
276
276
39
38
39
Mean
-2.18
-3.27
-7.56
-6.15
-1.10
-1.32
-1.90
-2.30
-1.50
SD
4.87
6.46
13.95
13.73
4.96
4.96
3.03
3.15
3.03
SGLT-2
Total
814
56
449
271
38
28
28
186
263
135.50
135.50
12.67
12.67
12.67
Mean
-0.26
-0.26
-5.57
-5.53
0.30
0.30
0.80
0.80
0.80
SD
5.35
5.35
13.64
13.78
5.06
5.06
3.30
3.30
3.30
Placebo
-4 -2 0 2 4
Mean difference
24-hr DBP
MD
-1.83
-2.41
-1.18
-1.51
-2.70
-1.92
-3.01
-1.99
-0.62
-1.40
-1.62
-2.70
-3.10
-2.30
95%-CI
[-2.35; -1.31]
[-9.30;  4.48]
[-9.75;  7.38]
[-2.91; -0.11]
[-3.69; -1.71]
[-4.27;  0.43]
[-5.62; -0.40]
[-4.79;  0.81]
[-2.96;  1.72]
[-2.43; -0.37]
[-2.65; -0.59]
[-4.75; -0.65]
[-5.17; -1.03]
[-4.35; -0.25]
Figure 4. Effect of SGLT2 inhibitors on 24-hour diastolic blood pressure. CANA indicates canagliflozin; DAPA, dapagliflozin; DBP,
diastolic blood pressure; EMPA, empagliflozin; ERTU, ertugliflozin; MD, mean difference; SGLT2, sodium-glucose cotransporter 2 inhibitor.
Figure 5. Contour-enhanced funnel plots of 24-hour diastolic blood pressure.
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with canagliflozin, dapagliflozin, empagliflozin, and ertugli-
flozin were 2.41 mm Hg (95% CI, 9.30 to 4.48),
1.18 mm Hg (95% CI, 9.75 to 7.38), 1.51 mm Hg
(95% CI, 2.91 to 0.11), and 2.70 mm Hg (95% CI,
3.69 to 1.71), respectively. A significant difference
between individual SGLT-2 inhibitors was noted (P<0.0001).
No strong evidence of small-study effects was observed
(Egger’s test P=0.15; Figure 5).
Daytime BP
An analysis of the 5 RCTs that reported daytime systolic BP
showed that SGLT2 inhibitor use was associated with a
statistically significant 4.34 mm Hg reduction when
compared with placebo (95% CI, 5.09 to 3.58; I2=0.90;
Figure 6).15–17,19,20 The mean differences observed with
canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin were
5.43 mm Hg (95% CI, 20.03 to 9.16), 4.31 mm Hg (95%
CI, 31.17 to 22.55), 4.14 mm Hg (95% CI, 8.71 to 0.43),
and4.37 mm Hg (95% CI,6.00 to2.74), respectively. No
significant difference between individual SGLT-2 inhibitors was
observed (P=0.75).
Only 3 RCTs reported data for daytime diastolic BP. We
found no studies that evaluated the effects of dapagliflozin on
daytime diastolic BP. SGLT2 inhibitor use was associated with
a statistically significant 2.09 mm Hg reduction in daytime
diastolic BP when compared with placebo (95% CI, 2.63 to
1.54; I2=0.80; Figure 7).15,19,20 The mean differences
observed with canagliflozin, empagliflozin, and ertugliflozin
were 2.58 mm Hg (95% CI, 7.90 to 2.74), 1.69 mm Hg
(95% CI, 3.60 to 0.22), and 2.80 mm Hg (95% CI, 3.30
to 2.30), respectively. A significant difference between
individual SGLT-2 inhibitors was noted (P<0.0001).
Nighttime BP
An analysis of the 5 RCTs that reported nighttime systolic BP
showed that SGLT2 inhibitor use was associated with a
statistically significant 2.61 mm Hg reduction when com-
pared with placebo (95% CI, 3.08 to 2.14; I2=0.99;
Figure 8).15–17,19,20 The mean differences observed with
canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin were
2.11 mm Hg (95%CI,18.94 to 14.71),2.05 mm Hg (95%
CI, 7.58 to 3.48), 2.85 mm Hg (95% CI, 4.44 to 1.26),
and2.46 mm Hg (95% CI,4.04 to0.87), respectively. No
significant difference between individual SGLT-2 inhibitors was
observed (P=0.25).
Only 3 RCTs reported data for nighttime diastolic BP. We
found no studies that evaluated the effects of dapagliflozin on
nighttime diastolic BP. SGLT2 inhibitor use was associated
Study
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Figure 6. Effect of SGLT2 inhibitors on daytime systolic blood pressure. CANA indicates canagliflozin; DAPA, dapagliflozin; EMPA,
empagliflozin; ERTU, ertugliflozin; MD, mean difference; SBP, systolic blood pressure; SGLT2, sodium-glucose cotransporter 2 inhibitor.
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with a statistically significant 1.49 mm Hg reduction in
nighttime diastolic BP when compared with placebo (95% CI,
2.20 to 0.78; I2=0.79; Figure 9).15,19,20 The mean differ-
ences observed with canagliflozin, empagliflozin, and ertugli-
flozin were 1.54 mm Hg (95% CI, 12.25 to 9.17),
1.14 mm Hg (95% CI, 1.45 to 0.82), and 2.49 mm Hg
(95% CI, 4.60 to 0.38), respectively. A significant differ-
ence between individual SGLT-2 inhibitors was observed
(P=0.02).
Metaregression
Random-effects metaregression analysis showed no signifi-
cant association between the 24-hour ambulatory systolic or
diastolic BP and either baseline BP (P=0.96, P=0.69, respec-
tively) or changes in body weight (P=0.44; P=0.88, respec-
tively). Because relatively few studies for each drug reported
24-hour ambulatory BP data, we could not perform meta-
regression by individual drug dose.
Discussion
This meta-analysis involving 2098 participants showed that
SGLT2 inhibitors significantly reduce 24-hour ambulatory
systolic BP by 3.76 mm Hg and 24-hour ambulatory
diastolic BP by 1.83 mm Hg. These results are similar to
a previous meta-analysis of seated clinic BP, which showed a
reduction in systolic BP of 3.8 mm Hg and diastolic BP of
1.6 mm Hg.5 Additionally, our results show that SGLT2
inhibitors significantly reduce daytime systolic and diastolic
BP and, to a lesser extent, nighttime systolic and diastolic BP.
The effects of SGLT2 inhibitors on 24-hour ambulatory BP
were consistent across the doses used in clinical trials. No
association was found between baseline BP and change in
body weight. Because direct comparisons between individual
agents could not be made, the reduction in 24-hour ambu-
latory BP observed with SGLT2 inhibitors should be consid-
ered a class effect.
The exact mechanism(s) through which SGLT2 inhibitors
lower BP are not completely understood, but are likely
multifactorial. SGLT2 inhibitors induce volume contraction
because of natriuretic and osmotic diuretic effects.1 Because
of chronic caloric deficit as a result of glucose excretion in the
urine, SGLT2 inhibitors can also induce weight loss and, more
important, body composition improvements by reduction of
fat mass with minor changes in lean mass.1,21 Fat mass
reduction has been reported to improve BP, proposing this as
an additional mechanism of BP reduction with SGLT2
Study
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Figure 7. Effect of SGLT2 inhibitors on daytime diastolic blood pressure. CANA indicates canagliflozin; DAPA, dapagliflozin; DBP, diastolic
blood pressure; EMPA, empagliflozin; ERTU, ertugliflozin; MD, mean difference; SGLT2, sodium-glucose cotransporter 2 inhibitor.
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inhibitors.1 Treatment with SGLT2 inhibitors also improves
arterial compliance, which is associated with improved BP.1
Furthermore, SGLT2 inhibitors reduce sympathetic nervous
system activity and, as recently suggested, renin-angiotensin-
aldosterone system activity by increasing sodium delivery at
the macula densa level in the kidney, both of which are
important determinants of BP.1,22 Further study is warranted
to identify the underlying mechanism(s) that contribute to the
apparent effects of SGLT2 inhibitors on BP.
In the current meta-analysis, it appears that the observed
BP reduction with SGLT2 inhibitors persists throughout a 24-
hour day with a greater percent reduction in BP during the
daytime compared with nighttime. This may be, in part,
attributed to the glucose-dependent nature of how SGLT2
inhibitors improve glycemic control, considering that osmotic
diuresis is likely increased during daytime periods of higher
caloric and fluid intake. Reduced urine production at night
attributed to circadian rhythms in kidney function may also
explain the reduced BP-lowering effect at nighttime. Of
course, the BP-lowering effect of SGLT2 inhibitors may also
be independent of diuresis, and differences in diurnal and
nocturnal BP regulation may reflect differences in sympathetic
tone.
The effects of other antihyperglycemic therapies on 24-
hour ambulatory BP have also been reported. In a study of
220 patients, metformin was shown to have no significant
effect on 24-hour ambulatory BP.23 Sitagliptin, at doses of
50 mg twice-daily and 100 mg twice-daily, produced a small,
but significant, reduction in 24-hour ambulatory systolic and
diastolic BP of 2.0 to 2.2 mm Hg and 1.6 to
1.8 mm Hg, respectively, when compared with placebo.24
Twice-daily exenatide25 and once-daily liraglutide26 have not
been shown to significantly reduce 24-hour ambulatory BP,
whereas dulaglutide 1.5 mg once-weekly significantly reduced
24-hour systolic BP by 2.8 mm Hg (95% CI, 4.6 to 1.0,
P≤0.001) compared with placebo.27 Interestingly, rosiglita-
zone significantly reduced 24-hour ambulatory systolic BP
(3.8 mm Hg) at both 6 and 12 months, when compared
with adding metformin (1.2 to 1.3 mm Hg; 6 months,
P=0.015; 12 months, P=0.031) to background sulfonylurea
therapy.28 Similar reductions with rosiglitazone were also
observed for 24-hour ambulatory diastolic BP. It is well
established that hyperinsulinemia resulting from insulin
resistance is associated with elevated BP; however, the
effects of exogenous insulin on BP are variable.29,30 Despite
the favorable effects of select antihyperglycemic therapies on
Study
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Figure 8. Effect of SGLT2 inhibitors on nighttime systolic blood pressure. CANA indicates canagliflozin; DAPA, dapagliflozin; EMPA,
empagliflozin; ERTU, ertugliflozin; MD, mean difference; SBP, systolic blood pressure; SGLT2, sodium-glucose cotransporter 2 inhibitor.
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24-hour ambulatory BP, none have been shown to improve
cardiovascular outcomes. This is possibly attributed to other
deleterious effects that may offset any benefit from a
reduction in 24-hour ambulatory BP, such as the increase in
plasma volume observed with thiazolidinediones.31 Our anal-
ysis demonstrates that the SGLT2 inhibitors are the only
known class to have a consistent and significant reduction in
24-hour ambulatory BP regardless of which agent is used.
The EMPA-REG OUTCOME trial3 was the first study to
demonstrate that an antihyperglycemic therapy, empagliflo-
zin, significantly reduces death from cardiovascular causes,
death from any cause, and hospitalization for heart failure.
Additionally, a prespecified analysis of the EMPA-REG
OUTCOME trial showed that empagliflozin also reduces
progression of diabetic nephropathy.32 In the EMPA-REG
OUTCOME study, empagliflozin reduced seated clinic systolic
BP by 4 to 6 mm Hg at week 16, whereas diastolic BP
was similar to placebo.3,33 Ongoing cardiovascular safety
trials with canagliflozin (CANVAS [CANagliflozin cardioVascu-
lar Assessment Study], NCT01032629) and dapagliflozin
DECLARE-TIMI 58 ([Dapagliflozin Effect on CardiovascuLAR
Events-TIMI 58], NCT01730534) will determine whether the
cardiovascular benefit of empagliflozin is a class effect. Much
remains to be determined regarding the specific mechanism
for how empagliflozin improves mortality and decreases heart
failure hospitalizations, yet it seems feasible that the reduc-
tions in BP would contribute.
It is important to note the limitations of this analysis. Study
protocols related to the measurement of 24-hour ambulatory
BP varied between studies, as did baseline BP. However,
metaregression showed no effects of SGLT2 inhibitors on BP
according to baseline BP. Additional heterogeneity in the
study populations also exists, such as presence or absence of
a hypertension diagnosis and use and duration of background
antihyperglycemic and antihypertensive therapies. Moreover,
we were unable to test whether the observed reduction in 24-
hour ambulatory BP would result in improvement in cardio-
vascular outcomes. The power of the statistical tests for
funnel plot symmetry is likely to be low because of less than
10 trials being included.
Conclusions
This meta-analysis shows that SGLT2 inhibitors significantly
improve overall 24-hour ambulatory BP and daytime and
nighttime BP in a diurnal fashion. The linear relationship
between 24-hour ambulatory BP and risk of cardiovascular
events, especially in patients with diabetes mellitus, suggests
that the favorable effects of SGLT2 inhibitors on 24-hour
ambulatory BP may, at least in part, contribute to a reduction in
cardiovascular risk.7,34,35 While additional study is warranted to
investigate mechanisms to describe the BP-lowering effects of
SGLT2 inhibitors and the impact of these effects on clinical
outcomes, these data highlight a unique characteristic of this
Study
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Figure 9. Effect of SGLT2 inhibitors on nighttime diastolic blood pressure. CANA indicates canagliflozin; DAPA, dapagliflozin; DBP, diastolic
blood pressure; EMPA, empagliflozin; ERTU, ertugliflozin; MD, mean difference; SGLT2, sodium-glucose cotransporter 2 inhibitor.
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class. It also emphasizes the need for monitoring BP outside of
the clinic through the use of home BP monitoring or 24-hour
ambulatory BPmonitoring, when available, to better monitor for
hypotension. Caution is warranted in individuals with lower
baseline BP and/or those already receiving diuretic therapies,
whereas volume status should also be monitored closely.36
Together with cardiovascular outcomes data from EMPA-REG
and this meta-analysis on 24-hour ambulatory BP, the evidence
continues to suggest a favorable effect of SGLT2 inhibitors on
cardiovascular outcomes in patients with diabetes mellitus.
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